Tablet-based Cognitive Assessment Tool (TabCAT) in a multisite study of early-onset Alzheimer's disease.
TabCAT digital measures have promise for frontline identification of patients with EOAD in a multisite study.
We begin our research endeavors with a solid foundation for study design and methodology. We have conducted systematic reviews of the current state of computerized assessments, led focus groups with primary care physicians to learn about their confidence and methods for diagnosing brain disorders, and reviewed qualitative results from feasibility studies in primary care settings.
We believe all novel assessments should be backed with evidence-based support before being used in clinical care. We have performed several types of validation with our tasks with sensitivity and specificity analyses, concurrent validity analyses, neuroanatomical validity analyses, and validation in several language adaptations across the globe.
Studies aimed at discovering links between TabCAT and biomarkers play a crucial role in early detection and diagnosis, treatment monitoring over time, and predicting change over time. We have seen significant associations between our tests and Aβ-PET and tau-PET status, and continue to perform research in this exciting field.
We believe in health equity for all, and the need for accessible tools is growing. We continue to validate our tools in multiple language adaptations, examine social determinants of health, and explore neurocognitive disorders in underserved populations such as those experiencing homelessness.
TabCAT digital measures have promise for frontline identification of patients with EOAD in a multisite study.
A culturally adapted TabCAT-BHA was validated in Peruvian older adults demonstrating strong reliability and accuracy for detecting cognitive impairment including in low-education and underserved populations.
Implementing TabCAT-BHA in primary care improved detection of cognitive impairment, increased clinician confidence, and demonstrated strong real-world scalability.
TabCAT-EXAMINER provides a reliable, valid composite measure of executive function for use in aging and neurodegenerative disease research and clinical trials.